Another great interview by Steve.
So its pretty clear from where I sit... oral mucosal spray form drug delivery has many benefits over other methods (pity he didnt mention the first pass effect through the liver but not to worry), and SUDA has the IP to become a world leader in this field.
Building a formidable business is what SC is doing.
We have the business model. We have the products, and when we trade sale Artimist or some of the SUDAMist products, we will have the serious funds to take strides forward.
Over time value should increase and reflect this IMO.
News: Suda highlights oral spray advantages , page-2
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.8¢ |
Change
-0.005(3.08%) |
Mkt cap ! $173.5M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 16.5¢ | 15.5¢ | $213.8K | 1.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 703028 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 414968 | 7 |
View Market Depth
| Last trade - 11.59am 03/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |